Medtronic Continues To Run (RNA) Interference With Biotech Firm Alnylam
This article was originally published in The Gray Sheet
Executive Summary
Medtronic is upping its investment in biotech drug delivery by expanding its collaboration with Alnylam for development of an RNA-based treatment for Huntington's disease
You may also be interested in...
Financings In Brief
Vital Therapies funds artificial liver development: Start-up raises $28.1 million in a "Series C" private placement to support further development of its ELAD extracorporeal liver assist device, the firm announces Sept. 12. The San Diego company is conducting a pivotal trial of the human cell-based artificial liver in China to support a planned near-term marketing application in that country, "and to provide more safety data for U.S. registration," according to the company. The firm anticipates Chinese approval this year and a U.S. market go-ahead by the end of the decade. ELAD, which is regulated as a biologic by FDA with input from the agency's device center, is intended as a bridge-to-transplant or for potential liver recovery for patients with severe liver failure. Vital Therapies acquired the bedside-use technology in 2003 from VitaGen (1"The Gray Sheet" Oct. 6, 2003, p. 26). The recent financing round was led by Versant Ventures
Financings In Brief
Vital Therapies funds artificial liver development: Start-up raises $28.1 million in a "Series C" private placement to support further development of its ELAD extracorporeal liver assist device, the firm announces Sept. 12. The San Diego company is conducting a pivotal trial of the human cell-based artificial liver in China to support a planned near-term marketing application in that country, "and to provide more safety data for U.S. registration," according to the company. The firm anticipates Chinese approval this year and a U.S. market go-ahead by the end of the decade. ELAD, which is regulated as a biologic by FDA with input from the agency's device center, is intended as a bridge-to-transplant or for potential liver recovery for patients with severe liver failure. Vital Therapies acquired the bedside-use technology in 2003 from VitaGen (1"The Gray Sheet" Oct. 6, 2003, p. 26). The recent financing round was led by Versant Ventures
Medtronic Invests In Gene Therapy Delivery For Parkinson’s Disease
Medtronic is extending its investment in gene therapy delivery to include neurological indications for Parkinson's disease and temporal lobe epilepsy under an agreement with Neurologix